Get the Stockscreener App
1.29
3.73%
-0.05
After Hours:
1.32
0.03
+2.33%
Tevogen Bio Holdings Inc stock is traded at $1.29, with a volume of 1.60M.
It is down -3.73% in the last 24 hours and up +27.72% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$1.34
Open:
$1.33
24h Volume:
1.60M
Relative Volume:
1.99
Market Cap:
$237.22M
Revenue:
-
Net Income/Loss:
$52.50M
P/E Ratio:
44.33
EPS:
0.0291
Net Cash Flow:
$-4.13M
1W Performance:
-1.53%
1M Performance:
+27.72%
6M Performance:
-1.53%
1Y Performance:
+66.67%
1-Day Range:
$1.27
$1.40
1-Week Range:
$1.25
$1.40
52-Week Range:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.29 | 240.90M | 0 | 52.50M | -4.13M | 0.0291 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen Bio expands AI in immunotherapy development By Investing.com - Investing.com South Africa
Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies - Nasdaq
Tevogen Details its Artificial Intelligence Initiative, - GlobeNewswire
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered ... - Bluefield Daily Telegraph
Tevogen Teams Up with Microsoft to Transform Healthcare: New AI Platform Targets $5T Industry - Stock Titan
Tariff Twist and PCE Ahead—Markets Hold Key Support - The Globe and Mail
This Raytheon Rival Is on Track to Hit New 52-Week Highs - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Sees Large Drop in Short Interest - Defense World
Tevogen Bio (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital - Defense World
4 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - Insider Monkey
Tevogen expands target for COVID treatment to seniors - Investing.com Australia
Tevogen expands target for COVID treatment to seniors By Investing.com - Investing.com Nigeria
Tevogen Bio Plans to Expand Specialty Care Pipeline to - GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business - GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting - The Manila Times
Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025 - Nasdaq
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited ... - Bluefield Daily Telegraph
Tevogen Unveils Massive $10B Portfolio Valuation and AI Expansion Ahead of Critical June Meeting - Stock Titan
Nvidia-Foxconn AI Alliance Could Disrupt the Supercomputer Market—What’s at Stake for Investors - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock Position Raised by Barclays PLC - Defense World
Tevogen Bio Holdings Inc. SEC 10-Q Report - TradingView
Tevogen Bio (NASDAQ:TVGN) Given “Buy” Rating at D. Boral Capital - Defense World
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - The Manila Times
Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition - Nasdaq
JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World
Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - ADVFN
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Shares Acquired by Geode Capital Management LLC - Defense World
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest - The Manila Times
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased ... - Bluefield Daily Telegraph
Tevogen Major Shareholders Choose DRS: Company to Release Step-by-Step Registration Guide Next Week - Stock Titan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - The Manila Times
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, ... - Bluefield Daily Telegraph
CD8 Technology Signs Letter of Intent for Tevogen Bio’s - GlobeNewswire
Tevogen Bio's $50M Manufacturing Expansion Backed by 74% Insider Ownership - Stock Titan
Tevogen sees launch year oncology business revenue $1B - Yahoo Finance
Tevogen highlights DRS account benefits for shareholders By Investing.com - Investing.com India
Tevogen Bio shares surge on revenue forecast By Investing.com - Investing.com Nigeria
Tevogen Bio shares surge on revenue forecast - Investing.com
Tevogen highlights DRS account benefits for shareholders - Investing.com
Direct Registration vs Brokerage: Tevogen Reveals Key Benefits for Shareholders - Stock Titan
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - The Manila Times
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - GlobeNewswire
Tevogen CEO Teams with Wall Street Giants to Navigate Biotech Market Volatility at BioNJ Conference - Stock Titan
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Tevogen CEO To Join Dialogue On Paths To Liquidity at BioNJ's Fifteenth Annual Bio Partnering Conference - marketscreener.com
Tevogen shares skyrocket as it projects $1B in revenue for its oncology pipeline - MSN
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Benzinga
Tevogen Bio Holdings Inc. Secures $50 Million Agreement with CD8 Technology Services to Enhance R&D and Manufacturing Capabilities - Nasdaq
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):